Cargando…

Vitiligoid hypopigmentation associated with pembrolizumab in metastatic head and neck cancer

Cutaneous adverse events are common with the use of immunotherapy. Although only 5% of patients develop severe reactions, about half will develop mild to moderate cutaneous adverse events. Vitiligo has been seen in melanomas treated with checkpoint inhibitors (CPI). We describe the first known case...

Descripción completa

Detalles Bibliográficos
Autor principal: Bulbul, Ajaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440267/
https://www.ncbi.nlm.nih.gov/pubmed/30949354
http://dx.doi.org/10.1093/omcr/omz016